Graig Suvannavejh
Stock Analyst at Mizuho
(4.59)
# 241
Out of 5,105 analysts
172
Total ratings
56.72%
Success rate
21.82%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Graig Suvannavejh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ERAS Erasca | Maintains: Outperform | $4 → $5 | $3.60 | +38.89% | 1 | Dec 9, 2025 | |
| TERN Terns Pharmaceuticals | Maintains: Outperform | $33 → $54 | $45.00 | +20.00% | 9 | Dec 9, 2025 | |
| BLTE Belite Bio | Upgrades: Outperform | $105 → $194 | $141.32 | +37.28% | 2 | Dec 2, 2025 | |
| INSM Insmed | Maintains: Outperform | $196 → $256 | $197.01 | +29.94% | 12 | Dec 1, 2025 | |
| HRMY Harmony Biosciences Holdings | Maintains: Outperform | $39 → $46 | $40.51 | +13.55% | 21 | Dec 1, 2025 | |
| TARS Tarsus Pharmaceuticals | Initiates: Outperform | $100 | $81.35 | +22.93% | 1 | Nov 20, 2025 | |
| IMTX Immatics | Maintains: Outperform | $19 → $23 | $10.04 | +129.08% | 4 | Nov 19, 2025 | |
| HALO Halozyme Therapeutics | Maintains: Neutral | $54 → $56 | $62.21 | -9.98% | 7 | Nov 18, 2025 | |
| IDYA IDEAYA Biosciences | Maintains: Outperform | $44 → $46 | $34.03 | +35.17% | 3 | Nov 11, 2025 | |
| AXSM Axsome Therapeutics | Maintains: Outperform | $200 → $202 | $148.17 | +36.33% | 22 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $24 → $19 | $25.23 | -24.69% | 11 | Nov 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $2 → $4 | $2.01 | +99.00% | 9 | Sep 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $0.68 | +4,343.13% | 1 | Sep 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $2.5 → $3.5 | $1.49 | +134.90% | 5 | Jul 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $4 → $5 | $2.09 | +139.23% | 2 | Jul 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $8 → $10 | $6.08 | +64.47% | 2 | Jun 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $11 | $8.37 | +31.42% | 3 | May 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $26 | $15.99 | +62.60% | 5 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $7 → $8 | $13.10 | -38.93% | 7 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $38 → $33 | $36.80 | -10.33% | 8 | Apr 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $7 → $7.6 | $1.61 | +372.05% | 1 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $74 | $9.70 | +662.89% | 1 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $50 → $5 | $3.92 | +27.55% | 3 | Sep 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $17 → $1 | $6.19 | -83.84% | 5 | Jun 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $31 → $35 | $113.56 | -69.18% | 5 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $9 → $8 | $23.81 | -66.40% | 6 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $71 → $57 | $63.35 | -10.02% | 2 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $8 → $5 | $31.35 | -84.05% | 4 | Apr 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $34 | $8.68 | +291.71% | 1 | Jun 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $28 | $9.43 | +196.92% | 1 | Apr 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $31 | $23.62 | +31.24% | 1 | Apr 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sell | $380 | $12.51 | +2,937.57% | 1 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $4.75 | $1.84 | +158.15% | 1 | Nov 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $36 | $29.02 | +24.05% | 2 | Nov 9, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | n/a | $31.69 | - | 1 | Oct 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $37 | $1.71 | +2,063.74% | 1 | Oct 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $128 | $167.50 | -23.58% | 1 | Sep 14, 2020 |
Erasca
Dec 9, 2025
Maintains: Outperform
Price Target: $4 → $5
Current: $3.60
Upside: +38.89%
Terns Pharmaceuticals
Dec 9, 2025
Maintains: Outperform
Price Target: $33 → $54
Current: $45.00
Upside: +20.00%
Belite Bio
Dec 2, 2025
Upgrades: Outperform
Price Target: $105 → $194
Current: $141.32
Upside: +37.28%
Insmed
Dec 1, 2025
Maintains: Outperform
Price Target: $196 → $256
Current: $197.01
Upside: +29.94%
Harmony Biosciences Holdings
Dec 1, 2025
Maintains: Outperform
Price Target: $39 → $46
Current: $40.51
Upside: +13.55%
Tarsus Pharmaceuticals
Nov 20, 2025
Initiates: Outperform
Price Target: $100
Current: $81.35
Upside: +22.93%
Immatics
Nov 19, 2025
Maintains: Outperform
Price Target: $19 → $23
Current: $10.04
Upside: +129.08%
Halozyme Therapeutics
Nov 18, 2025
Maintains: Neutral
Price Target: $54 → $56
Current: $62.21
Upside: -9.98%
IDEAYA Biosciences
Nov 11, 2025
Maintains: Outperform
Price Target: $44 → $46
Current: $34.03
Upside: +35.17%
Axsome Therapeutics
Nov 6, 2025
Maintains: Outperform
Price Target: $200 → $202
Current: $148.17
Upside: +36.33%
Nov 3, 2025
Maintains: Neutral
Price Target: $24 → $19
Current: $25.23
Upside: -24.69%
Sep 12, 2025
Maintains: Neutral
Price Target: $2 → $4
Current: $2.01
Upside: +99.00%
Sep 8, 2025
Initiates: Outperform
Price Target: $30
Current: $0.68
Upside: +4,343.13%
Jul 28, 2025
Upgrades: Outperform
Price Target: $2.5 → $3.5
Current: $1.49
Upside: +134.90%
Jul 16, 2025
Maintains: Outperform
Price Target: $4 → $5
Current: $2.09
Upside: +139.23%
Jun 18, 2025
Maintains: Outperform
Price Target: $8 → $10
Current: $6.08
Upside: +64.47%
May 20, 2025
Maintains: Outperform
Price Target: $12 → $11
Current: $8.37
Upside: +31.42%
May 16, 2025
Maintains: Outperform
Price Target: $30 → $26
Current: $15.99
Upside: +62.60%
May 14, 2025
Maintains: Outperform
Price Target: $7 → $8
Current: $13.10
Upside: -38.93%
Apr 7, 2025
Maintains: Neutral
Price Target: $38 → $33
Current: $36.80
Upside: -10.33%
Nov 18, 2024
Upgrades: Buy
Price Target: $7 → $7.6
Current: $1.61
Upside: +372.05%
Sep 20, 2024
Reiterates: Outperform
Price Target: $74
Current: $9.70
Upside: +662.89%
Sep 19, 2024
Downgrades: Neutral
Price Target: $50 → $5
Current: $3.92
Upside: +27.55%
Jun 5, 2023
Downgrades: Neutral
Price Target: $17 → $1
Current: $6.19
Upside: -83.84%
Nov 10, 2022
Maintains: Buy
Price Target: $31 → $35
Current: $113.56
Upside: -69.18%
Nov 10, 2022
Maintains: Neutral
Price Target: $9 → $8
Current: $23.81
Upside: -66.40%
May 24, 2022
Maintains: Buy
Price Target: $71 → $57
Current: $63.35
Upside: -10.02%
Apr 19, 2022
Maintains: Sell
Price Target: $8 → $5
Current: $31.35
Upside: -84.05%
Jun 1, 2021
Initiates: Buy
Price Target: $34
Current: $8.68
Upside: +291.71%
Apr 20, 2021
Initiates: Neutral
Price Target: $28
Current: $9.43
Upside: +196.92%
Apr 19, 2021
Initiates: Neutral
Price Target: $31
Current: $23.62
Upside: +31.24%
Mar 2, 2021
Initiates: Sell
Price Target: $380
Current: $12.51
Upside: +2,937.57%
Nov 24, 2020
Initiates: Neutral
Price Target: $4.75
Current: $1.84
Upside: +158.15%
Nov 9, 2020
Upgrades: Buy
Price Target: $36
Current: $29.02
Upside: +24.05%
Oct 21, 2020
Downgrades: Sell
Price Target: n/a
Current: $31.69
Upside: -
Oct 20, 2020
Initiates: Neutral
Price Target: $37
Current: $1.71
Upside: +2,063.74%
Sep 14, 2020
Downgrades: Sell
Price Target: $128
Current: $167.50
Upside: -23.58%